Compare Medtronic PLC (MDT) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Medtronic PLC trades at $82.37 (market cap $106.61B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $118.08. The key difference: Medtronic PLC pays a 3.46% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| MDT | QQQE | |
|---|---|---|
Market Cap | $106.61B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $105.35 | $122.72 |
52-Week Low | $73.75 | $96.06 |
Enterprise Value | $125.36B | — |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
QQQE trades at $116.70, down 0.09% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap-weighted peers. Recent news highlights its defensive appeal amid market shifts, with SpaceX's imminent Nasdaq-100 inclusion potentially driving passive inflows.
The outlook balances diversification benefits against market volatility risks. Equal weighting provides stability if mega-cap tech underperforms, but the bearish technical trend and neutral oscillators suggest near-term caution. Investors seeking Nasdaq exposure with lower single-stock risk may find QQQE attractive, though monitoring index rebalancing impacts is crucial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
